As the article states, you don’t need marketing for cancer drugs, as the need is unfortunately already there, thus marketing for cancer drugs does not necessarily carry the same sales expense as do other drugs. We have all seen the “tiered plans” on what level drugs are listed with insurance coverage...
Posted to
The Medical Quack .... by Barbara Duck
on 10-13-2008
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, personalized medicine, Genomics, health insurance, Pharma, Prescriptions, Cancer, R and D, Science 2.0
Medical Quack on Reuters. Now this is a sad state of affairs to be the prudent consumer, and yet you are potentially taking money out of your doctor's pocket by doing so when it comes to pay for performance for them, so what's up with this when purchasing $4.00 Generic Drugs. BD...
Posted to
The Medical Quack .... by Barbara Duck
on 09-18-2008
Filed under: Medically Related, Insurance, Pharma/FDA News, My Commentaries, health insurance, Physicians, Pharma, HMO, Generic Drugs, Pay for Performance, Patients
More additional affiliations for the FDA to gather information. In the news recently have been other agreements with companies such as Blue Cross and others who will be providing data to also study the effects of drugs through medical record information in their files, based on claims, etc. No...
Posted to
The Medical Quack .... by Barbara Duck
on 08-18-2008
Filed under: Medically Related, Technology, Insurance, Pharma/FDA News, health insurance, healthcare IT, Pharma, Biotech, FDA, Medco, Pharmacogonomics